These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 6994978)

  • 1. Influence of age and smoking on drug kinetics in man: studies using model compounds.
    Vestal RE; Wood AJ
    Clin Pharmacokinet; 1980; 5(4):309-19. PubMed ID: 6994978
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of aging and cigarette smoking on antipyrine and indocyanine green elimination.
    Wood AJ; Vestal RE; Wilkinson GR; Branch RA; Shand DG
    Clin Pharmacol Ther; 1979 Jul; 26(1):16-20. PubMed ID: 445957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Fluosol-DA hemodilution on the kinetics of hepatically eliminated drugs.
    Shrewsbury RP
    Res Commun Chem Pathol Pharmacol; 1987 Mar; 55(3):375-96. PubMed ID: 3575876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enzyme induction and beta-adrenergic receptor blocking drugs.
    Branch RA; Herman RJ
    Br J Clin Pharmacol; 1984; 17 Suppl 1(Suppl 1):77S-84S. PubMed ID: 6146342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical significance of the effects of cigarette smoking on drug disposition.
    Luczynska C; Wilson K
    Methods Find Exp Clin Pharmacol; 1983 Sep; 5(7):479-87. PubMed ID: 6366402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased clearance of antipyrine and d-propranolol after phenobarbital treatment in the monkey. Relative contributions of enzyme induction and increased hepatic blood flow.
    Branch RA; Shand DG; Wilkinson GR; Nies AS
    J Clin Invest; 1974 Apr; 53(4):1101-7. PubMed ID: 4205524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of acute withdrawal from cigarette smoking on indocyanine green and antipyrine clearance.
    Eldon MA; Luecker PW; MacGee J; Ritschel WA
    J Clin Pharmacol; 1987 Mar; 27(3):226-32. PubMed ID: 3680579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics in the elderly.
    Crooks J; O'Malley K; Stevenson IH
    Clin Pharmacokinet; 1976; 1(4):280-96. PubMed ID: 797500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beta-adrenoceptor blocking drugs and cytochrome P-450: the influence of propranolol treatment on caffeine, antipyrine, D-glucaric acid and indocyanine green elimination in patients with hepatic disorders.
    Traeger A; Horváth T; Rechenbach C; Jávor T
    Int J Clin Pharmacol Res; 1986; 6(3):235-9. PubMed ID: 3744626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic drug interactions with propranolol.
    Wood AJ; Feely J
    Clin Pharmacokinet; 1983; 8(3):253-62. PubMed ID: 6342901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of age and cigarette smoking on propranolol disposition.
    Vestal RE; Wood AJ; Branch RA; Shand DG; Wilkinson GR
    Clin Pharmacol Ther; 1979 Jul; 26(1):8-15. PubMed ID: 445965
    [No Abstract]   [Full Text] [Related]  

  • 12. Beta-adrenergic blockade affects initial drug distribution due to decreased cardiac output and altered blood flow distribution.
    Avram MJ; Krejcie TC; Henthorn TK; Niemann CU
    J Pharmacol Exp Ther; 2004 Nov; 311(2):617-24. PubMed ID: 15197245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proceedings: The influence of chronic liver disease on the elimination of d-propranolol, anti-pyrine, and indocyanine green.
    Branch RA; James JA; Read AE
    Gut; 1974 Oct; 15(10):837-8. PubMed ID: 4434964
    [No Abstract]   [Full Text] [Related]  

  • 14. The relationship between liver volume, antipyrine clearance and indocyanine green clearance before and after phenobarbitone administration in man.
    Roberts CJ; Jackson L; Halliwell M; Branch RA
    Br J Clin Pharmacol; 1976 Oct; 3(5):907-13. PubMed ID: 973986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antipyrine metabolism in man: influence of age, alcohol, caffeine, and smoking.
    Vestal RE; Norris AH; Tobin JD; Cohen BH; Shock NW; Andres R
    Clin Pharmacol Ther; 1975 Oct; 18(4):425-32. PubMed ID: 1164824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug metabolism in diabetic subjects with fatty livers.
    Pirttiaho HI; Salmela PI; Sotaniemi EA; Pelkonen RO; Pitkänen U; Luoma PV
    Br J Clin Pharmacol; 1984 Dec; 18(6):895-9. PubMed ID: 6529530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impairment of hepatic drug metabolism in patients with acute viral hepatitis.
    Narang AP; Datta DV; Nath N; Mathur VS
    Eur J Drug Metab Pharmacokinet; 1982; 7(4):255-8. PubMed ID: 7166177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Drug metabolism in liver diseases].
    Paumgartner G
    Z Gastroenterol Verh; 1979; 16():42-7. PubMed ID: 95370
    [No Abstract]   [Full Text] [Related]  

  • 19. Indocyanine green clearance following single and chronic cimetidine doses.
    MacKichan JJ; Schaal SF; Stine RA; Boudoulas H
    Res Commun Chem Pathol Pharmacol; 1984 May; 44(2):323-6. PubMed ID: 6739959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of acute and chronic exercise on hepatic drug metabolism.
    Døssing M
    Clin Pharmacokinet; 1985; 10(5):426-31. PubMed ID: 3899456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.